Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma.

ABSTRACT: Cholangiocarcinoma (CCA), a group of malignancies that originate from the biliary tract, is associated with a high mortality rate and a concerning increase in worldwide incidence. In Thailand, where the incidence of CCA is the highest, the socioeconomic burden is severe. Yet, treatment options are limited, with surgical resection being the only form of treatment with curative intent. The current standard-of-care remains adjuvant and palliative chemotherapy which is ineffective in most patients. The overall survival rate is dismal, even after surgical resection and the tumor heterogeneity further complicates treatment. Together, this makes CCA a significant burden in Southeast Asia. For effective management of CCA, treatment must be tailored to each patient, individually, for which an assor

SUBMITTER: Balasubramanian B 

PROVIDER: S-EPMC7826774 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature